06:28 AM EDT, 08/28/2026 (MT Newswires) -- Clinical-stage pharmaceutical company Oncozenge (ONCOZ.ST) entered into a 2 million-krona bridge financing deal with John Haurum ahead of its planned 33.3 million-krona rights issue. The loan has an arrangement fee of 5% and interest of 1.5% per month, according to a Friday release. The lender may also request that the outstanding loan amount, including accrued interest, be converted into new shares through a directed share issue.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.